Cited 0 times in
Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안성귀 | - |
dc.contributor.author | 정준 | - |
dc.date.accessioned | 2021-09-29T00:59:27Z | - |
dc.date.available | 2021-09-29T00:59:27Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184136 | - |
dc.description.abstract | Purpose: In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels. Methods: In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS): low, intermediate, and high (AS 3-4, 5-6, and 7-8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate. Results: Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8-96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity. Conclusion: Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression. Trial registration: ClinicalTrials.gov Identifier: NCT01069211. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean, English | - |
dc.publisher | Korean Breast Cancer Society | - |
dc.relation.isPartOf | JOURNAL OF BREAST CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Sung Gwe Ahn | - |
dc.contributor.googleauthor | Seok Jin Nam | - |
dc.contributor.googleauthor | Sei Hyun Ahn | - |
dc.contributor.googleauthor | Yongsik Jung | - |
dc.contributor.googleauthor | Heung Kyu Park | - |
dc.contributor.googleauthor | Soo Jung Lee | - |
dc.contributor.googleauthor | Sung Soo Kang | - |
dc.contributor.googleauthor | Wonshik Han | - |
dc.contributor.googleauthor | Kyong Hwa Park | - |
dc.contributor.googleauthor | Yong Lai Park | - |
dc.contributor.googleauthor | Jihyoun Lee | - |
dc.contributor.googleauthor | Hyun Jo Youn | - |
dc.contributor.googleauthor | Jun Hyun Kim | - |
dc.contributor.googleauthor | Youngbum Yoo | - |
dc.contributor.googleauthor | Jeong Yoon Song | - |
dc.contributor.googleauthor | Byung Kyun Ko | - |
dc.contributor.googleauthor | Geumhee Gwak | - |
dc.contributor.googleauthor | Min Sung Chung | - |
dc.contributor.googleauthor | Sung Yong Kim | - |
dc.contributor.googleauthor | Seo Heon Cho | - |
dc.contributor.googleauthor | Doyil Kim | - |
dc.contributor.googleauthor | Myung Chul Chang | - |
dc.contributor.googleauthor | Byung In Moon | - |
dc.contributor.googleauthor | Lee Su Kim | - |
dc.contributor.googleauthor | Sei Joong Kim | - |
dc.contributor.googleauthor | Min Ho Park | - |
dc.contributor.googleauthor | Tae Hyun Kim | - |
dc.contributor.googleauthor | Jihyoung Cho | - |
dc.contributor.googleauthor | Cheol Wan Lim | - |
dc.contributor.googleauthor | Young Tae Bae | - |
dc.contributor.googleauthor | Gyungyub Gong | - |
dc.contributor.googleauthor | Young Kyung Bae | - |
dc.contributor.googleauthor | Ahwon Lee | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.identifier.doi | 10.4048/jbc.2021.24.e17 | - |
dc.contributor.localId | A02231 | - |
dc.contributor.localId | A03727 | - |
dc.relation.journalcode | J01279 | - |
dc.identifier.eissn | 2092-9900 | - |
dc.identifier.pmid | 33818022 | - |
dc.subject.keyword | Breast neoplasms | - |
dc.subject.keyword | Letrozole | - |
dc.subject.keyword | Postmenopause | - |
dc.subject.keyword | Receptors, estrogen | - |
dc.contributor.alternativeName | Ahn, Sung Gwe | - |
dc.contributor.affiliatedAuthor | 안성귀 | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 164 | - |
dc.citation.endPage | 174 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, Vol.24(2) : 164-174, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.